scholarly journals Experience of the use of combined phytopreparations in the treatment of respiratory tract diseases

2018 ◽  
Vol 22 (1) ◽  
pp. 46-50
Author(s):  
V.M. Dudnyk ◽  
I.V. Моrozova ◽  
M.O. Shalamai ◽  
Y.V. Vyzhga
Keyword(s):  
Respiratory Tract ◽  
Viral Infection ◽  
Integrated Management ◽  
Age Groups ◽  
Clinical Effectiveness ◽  
Main Group ◽  
Control Group ◽  
Upper Respiratory Tract ◽  
Modern Approach ◽  
Upper Respiratory

The article showed the problem of integrated management of children different age groups with upper respiratory tract viral infection. It reflected modern approach of using multicomponent herbal medicine for cough therapy in children in the practice of pediatrician. We evaluated necessity of the prescription and effect of the herbal drug in syrup type Gamma in case of acute respiratory diseases in 50 children, from the age of 2 up to 15 years of life, that were treated at infectious-diagnostic department of Vinnytsya regional children’s hospital and had cough symptom. Analysis of the results of the use of herbal multicomponent Gamma syrup in children with cough was provided. The duration of the cough period, qualitative changes in the cough symptom, such as frequency and expectoration of sputum were analyzed. In every case we estimated time of cough originating, changes of its characteristics from the dry to productive, decreasing of the intensity and time of the clinical recovering. The effectiveness of Gamma syrup was evaluated by comparing the main group of patients and the control group. In 92% of patients in the main group on day 7 cough completely stopped, comparing to the control group –cough stopped in 52%. This is the evidence of positive effect on cough, sputum discharge, it`s viscosity and common improvement of drainage function respiratory tract. Using of herbal multicomponent Gamma syrup shows high clinical effectiveness as mucolytic, broncholytic, expectorant and anti-inflammatory drug in children with cough in complex treatment of upper respiratory tract viral infection.

scholarly journals Effectiveness of the low-molecular inductor of interferon of Amiksin® in treatment and preventive maintenance of the chronic recurrent inflammatory diseases of the upper respiratory tract

2016 ◽  
Vol 15 (2) ◽  
pp. 66-75
Author(s):  
A. E. Shulzhenko ◽  
I. N. Zuikova ◽  
A. V. Karaulov ◽  
R. V. Shchubelko
Keyword(s):  
Respiratory Tract ◽  
Inflammatory Diseases ◽  
Main Group ◽  
Control Group ◽  
Symptomatic Therapy ◽  
Upper Respiratory Tract ◽  
Chronic Inflammatory Diseases ◽  
Barr Virus ◽  
Upper Respiratory ◽  
Interferon Inductor

Introduction. In the formation of recurrent and/or prolonged chronic inflammatory diseases of the upper respiratory tract in addition to the known, previously studied, factors that play an important role in the violation of the human immune system at the level of local (mucosal) and systemic immunity and activation of herpes virus group (Epstein Virus Barr virus, cytomegalovirus, herpes simplex virus type 6). In the treatment of herpesvirus infections, activation of antiviral immunity in domestic medicine used drugs interferon inducer. Objective. To evaluate the efficacy of interferon inductor Amiksin® in patients with chronic recurrent inflammatory diseases of the upper respiratory tract. Materials and methods. Based on separation of “Allergy and Immunotherapy” SSC “Institute of Immunology” FMBA studied low-molecular interferon inductor Amixin® (JSC “Pharmstandard-Tomskhimpharm”, Russia) in the treatment of chronic recurrent inflammatory diseases of the upper respiratory tract. The study included 40 patients between men and women, aged 18 to 65years old with a history of recurrent chronic inflammatory diseases of the upper respiratory tract. Clinical research methods included a medical history, previous efficiency of the treatment, the presence of comorbidities. Laboratory methods include bacteriological crop on flora in the material from the oropharynx and the detection of DNA viruses of herpes group in saliva. Patients of the main group, after clinical and laboratory examination, prescribed therapy with Amixin®. Patients in both groups received symptomatic therapy. The total duration of observation of each patient was 3 months. Results. Amiksin® receiving the drug in patients with acute exacerbation of chronic recurrent upper respiratory tract inflammatory diseases contributed to a more rapid relief of general and local symptoms. Also it found that reduces performance Amiksin® average viral load against Epstein-Barr virus. Over the next 3 months follow-up, 25 % of patients the main group marked exacerbation study pathology of the upper respiratory tract, in the control group of patients with recurrent exacerbations were more - 60 %, indicating that preventive action Amiksin® therapy. Conclusions: The use of low-molecular interferon inductor Amiksin®(JSC “Pharmstandard-Tomskhimpharm”, Russia) in the combined therapy showed good efficacy in reducing the concentration of chronic viral infections in the oropharynx and prevention of chronic relapsing inflammatory diseases of the upper respiratory tract.

scholarly journals Route of Nutrition Influences Generation of Antibody-Forming Cells and Initial Defense to an Active Viral Infection in the Upper Respiratory Tract

2003 ◽  
Vol 237 (4) ◽  
pp. 565-573 ◽  
Author(s):  
Cheryl D. Johnson ◽  
Kenneth A. Kudsk ◽  
Kazuhiko Fukatsu ◽  
Kathryn B. Renegar ◽  
Ben L. Zarzaur
Keyword(s):  
Respiratory Tract ◽  
Viral Infection ◽  
Upper Respiratory Tract ◽  
Upper Respiratory

scholarly journals A role of oropharyngeal microbiota in developing acute and chronic diseases of the upper respiratory tract

2020 ◽  
Vol 10 (2) ◽  
pp. 359-367
Author(s):  
I. I. Ababii ◽  
L. A. Danilov ◽  
M. K. Maniuc ◽  
P. I. Ababii ◽  
S. S. Ghinda ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Chronic Tonsillitis ◽  
Upper Respiratory Tract Infections ◽  
Control Group ◽  
Healthy Children ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Tract Infections

Currently, a rise in incidence of polyethological inflammation of the upper respiratory tract mucosa paralleled by altered resident and transient microbiota displaying in many cases increased antibiotic resistance has been noted. Opportunistic microbes play a major role in developing inflammatory process in Pirogov–Waldeyer’s ring. An inflammatory process occurring in the tonsillar lymphatic tissue results in host systemic complications. Fighting against acute and chronic infections of the upper respiratory tract holds the main task in pediatric otorhinolaryngology, as they can consequently elicit the cardiovascular, genitourinary and musculoskeletal complications. The results of studies examining this issue remain very contradictory, which accounted for a need to conduct our study on the territory of Moldova featured with mixed climatic conditions. Here, we wanted to study a role of microbial factor in etiopathogenesis of chronic tonsillitis in children. Bacteriological microbiota data for superficial palatine tonsils were obtained form 608 children subdivided into 5 groups: group I — 333 children with compensated chronic tonsillitis; group II — 87 children with decompensated chronic tonsillitis; group III — 91 children with acute upper respiratory tract infections (comparison group); group IV — 48 children with acute upper respiratory tract infections treated with antibiotic therapy; group V — 49 apparently healthy children (control group). It was found that β-hemolytic streptococcus exerting high sensitivity to virtually all antibiotics groups was detected in 17.4% of children with acute tonsilar inflammatory processes and decompensated defense in the lymphatic pharyngeal ring compared to 3.5% in control group. Streptococcus pneumoniae was isolated in all study groups ranging within 4.8–21.7%, including 14% in apparently healthy children characterized by reduced antibiotics sensitivity. The data obtained suggest that sickly children with acute and chronic upper respiratory tract infections constitute a risk group for developing somatic diseases. The high incidence of Streptococcus pneumoniae indicates a need for performing immunoprophylaxis, use of therapeutic vaccination as a up-to-date, combined approach in treatment of such pediatric cohort.

scholarly journals Assessment of Postvaccine Immunity against Streptococcus pneumoniae in Patients with Asplenia, including an Analysis of Its Impact on Bacterial Flora of the Upper Respiratory Tract and Incidence of Infections

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Alina Olender ◽  
Katarzyna Małkińska ◽  
Jacek Roliński ◽  
Ewelina Grywalska ◽  
Elżbieta Pels ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Bacterial Flora ◽  
Carrier State ◽  
Control Group ◽  
Pathogenic Microorganisms ◽  
Upper Respiratory Tract ◽  
Specific Antibodies ◽  
Positive Effects ◽  
Upper Respiratory ◽  
Potentially Pathogenic Microorganisms

S. pneumoniae is a microorganism that may cause a serious threat in postsplenectomy patients due to a potentially invasive course of infection. In order to assess a protective activity after vaccination with the 23-valent vaccine, we made an analysis of the level of antibodies in patients with asplenia compared to a control group of healthy donors. Additionally, colonization by potentially pathogenic microorganisms of the upper respiratory tract was analyzed to determine the carrier state by strains with vaccine serotype. No such strains were found in the research, yet three non-vaccine-serotype strains were found. Colonization of the upper respiratory tract by potentially pathogenic microorganisms may be connected with increased susceptibility observed and incidence of infections in patients with asplenia. However, colonization by S. pneumoniae may not have an effect on the level of specific antibodies with the 23-valent vaccine against S. pneumoniae (PPV23) in postsplenectomy patients and healthy people. The response to vaccination against S. pneumoniae showed a lower level of specific antibodies in patients with splenectomy performed more than 2 years before the test than in patients with a recently removed spleen, i.e., from 1 month to 2 years before the test. Vaccination against pneumococci also has positive effects on incidence of other etiology infections, which is of high significance in the prophylaxis of infectious diseases in this group of patients.

scholarly journals Oral intake of heat-killedLactobacillus plantarumL-137 decreases the incidence of upper respiratory tract infection in healthy subjects with high levels of psychological stress

2013 ◽  
Vol 2 ◽  
Author(s):  
Yoshitaka Hirose ◽  
Yoshihiro Yamamoto ◽  
Yasunobu Yoshikai ◽  
Shinji Murosaki
Keyword(s):  
Tract Infection ◽  
Respiratory Tract ◽  
Concanavalin A ◽  
Healthy Subjects ◽  
Human Subjects ◽  
Oral Intake ◽  
Control Group ◽  
Upper Respiratory Tract ◽  
Immune Functions ◽  
Upper Respiratory

AbstractThe immunomodulatory effects of live or non-viable lactic acid bacteria have been extensively investigated. We reported that oral intake of heat-killedLactobacillus plantarumL-137 (HK L-137) augmented innate and acquired immunity in mice and human subjects. To examine the effects of HK L-137 intake on upper respiratory tract infection (URTI) symptoms and immune functions in human subjects, a randomised, double-blind, placebo-controlled, parallel study was conducted in subjects with high psychological stress levels. A total of seventy-eight healthy subjects (thirty-three men and forty-five women; mean age 50·6 years) with scores of >41 on eighteen-item subscales of psychological distress in the Brief Job Stress Questionnaire were randomly assigned to receive a tablet containing HK L-137 (10 mg) or a placebo tablet daily for 12 weeks. The URTI symptoms were rated once daily on the validated twenty-one-item Wisconsin Upper Respiratory Symptom Survey-21. Immune functions, such as concanavalin A-induced proliferation and percentages of interferon (IFN)-γ- and IL-4-producing CD4 T cells of peripheral blood mononuclear cells (PBMC), and serum IFN-β concentrations were measured every 4 weeks. URTI incidence was significantly lower in the HK L-137 group than in the control group. URTI incidence, duration and severity, and duration of medication showed significant negative correlations with duration of HK L-137 intake. The percentage change from baseline of concanavalin A-induced proliferation of PBMC was significantly greater in the HK L-137 group than in the control group. These findings suggest that daily HK L-137 intake can decrease URTI incidence in healthy subjects, possibly through augmentation of immune functions.

Echinacea purpurea L. in children: safety, tolerability, compliance, and clinical effectiveness in upper respiratory tract infectionsThis article is one of a selection of papers published in this special issue (part 2 of 2) on the Safety and Efficacy of Natural Health Products.

2007 ◽  
Vol 85 (11) ◽  
pp. 1195-1199 ◽  
Author(s):  
Paul Richard Saunders ◽  
Fraser Smith ◽  
Read Weaver Schusky
Keyword(s):  
Respiratory Tract ◽  
Clinical Effectiveness ◽  
Echinacea Purpurea ◽  
Natural Health Products ◽  
Upper Respiratory Tract ◽  
Natural Health ◽  
Health Products ◽  
Upper Respiratory ◽  
Tract Infections ◽  
Echinacea Extract

Echinacea purpurea (L.) Moench was mistakenly taken from North America to Germany in 1939 where it was cultivated and various extractions were prepared and subsequently used to treat upper respiratory tract infections. Parents often administer Echinacea to their children, but safety data on the use of Echinacea in Canadian children is lacking. A screening history, physical examination, and daily record of symptoms from an initial visit through to a the follow-up visit 13 days later were used to increase patient safety. Each subject was administered an aerial part Echinacea extract. The dose was based on age (2.5 mL three times per day for children aged 2–5 years, and 5 mL two times per day for children aged 6–12 years) and administered for 10 days in an open-label trial. A rating scale was used to measure tolerance to the treatment. We assessed the safety and compliance of use of the Echinacea extract by measuring the amount of extract returned at the end of the study, having the parents complete and return a daily symptom diary, and recording the subjects’ use of other natural health products or medications during the trial. Clinical effectiveness of the Echinacea extract could not be accurately assessed because of the small trial size and because the extract had been administered when some of the subjects had an upper respiratory tract infection that had begun 1 or more days prior to the study; however, each subject’s symptoms improved. No allergic or adverse reaction occurred and no safety issues arose.

scholarly journals Effects of the upper respiratory tract cross-section on the vertical and sagittal dimension and the facial axis according to Ricketts

2018 ◽  
Vol 14 (3) ◽  
pp. 178-191
Author(s):  
Anna Duda ◽  
Wojciech Stós ◽  
Magdalena Wiosna
Keyword(s):  
Respiratory Tract ◽  
Subjective Evaluation ◽  
Threshold Value ◽  
Control Group ◽  
Upper Respiratory Tract ◽  
Facial Skeleton ◽  
Basic Parameters ◽  
Upper Respiratory ◽  
And Control ◽  
Anterior Angle

This study assesses the effects of the upper respiratory tract width at the level of the adenoid in patients with a normal and abnormal breathing route on basic parameters of the morphology of the facial skeleton. <b>Aim.</b> Comparison of skeletal parameters determining vertical (SNL/ML, NL/ML, NL/ML), sagittal (SNA, SNB) dimensions and type of facial rotation (the angle of the facial axis according to Ricketts) in the study and control groups and determination of the threshold value (a cut-off point) of width according to Holmberg, at which there is a deviation from the average values of basic parameters of morphology of the facial skeleton. <b>Material and methods.</b> The study included 221 patients treated at an orthodontic clinic in Kielce. Based on the medical history taken, clinical examination and subjective evaluation of the upper respiratory tract width according to Holmberg 112 patients were enrolled into the study group and 109 patients into the control group. The width of the upper respiratory tract was measured using the modified Holmberg method and parameters assessing the vertical (SNL/ML, NL/ML) and sagittal (SNA, SNB) dimensions, as well as the anterior angle of the Ricketts’ axis were measured using the analysis of lateral teleroentgenograms of the head. <b>Results.</b> All compared skeletal parameters indicated significant statistical differences between the study and control group. These differences were: Ricketts’ angle 6.5°, SNL/ML 8.5°, NL/ML 9.7°, SNA 2.4°, SNB 1.4°. <b>Conclusions.</b> The width of the upper respiratory tract at the level of the adenoid significantly affects values of skeletal parameters evaluating the vertical (SNL/ML, NL/ML) and sagittal (SNA, SNB) dimensions and the type of rotation of the facial axis. There is a correlation between a gradual decrease in the airway dimension according to Holmberg and an increase in the vertical dimension (SNL/ML, NL/ML) and anterior angle of the Ricketts’ facial axis (posterior rotation of the mandible) and a decrease in the sagittal dimension (SNA, SNB).

scholarly journals Spectrum of Influenza B Viral Infection in Indian Children: A Tertiary Centre Experience

2018 ◽  
Vol 38 (3) ◽  
pp. 170-175 ◽  
Author(s):  
Sandesh Kini ◽  
Ramesh Bhat Y ◽  
Koushik Handattu ◽  
Phalguna Kousika ◽  
Chennakeshava Thunga
Keyword(s):  
Tract Infection ◽  
Respiratory Tract ◽  
Viral Infection ◽  
Respiratory Tract Infection ◽  
Severe Pneumonia ◽  
Upper Respiratory Tract Infection ◽  
Influenza B Virus ◽  
Influenza B ◽  
Upper Respiratory Tract ◽  
Upper Respiratory

Introduction: Influenza viral infection in children can range from subclinical illness to multi system involvement. The morbidity associated with influenza B viral infection is often overlooked. India being the second most populous country, accounts for 20% of global childhood deaths from respiratory infections. There is paucity of data on the clinical features and complications of influenza B viral infections in children from the Indian subcontinent. Our objective was to study the clinical profile, seasonality, complications and outcome associated with Influenza B viral infection in children < 18 years of age. Material and Methods: We conducted a retrospective observational study at a tertiary care hospital in South India. Children less than 18 years of age admitted to our paediatric unit were included in the study. We reviewed the case sheets of 56 patients who tested positive for influenza B virus during the study period and recorded their clinical and laboratory data. Throat swab obtained from cases were tested by RT-PCR. The illness was classified as upper respiratory tract infection, pneumonia and severe pneumonia. Outcome measures analysed were- mortality, need for oxygen supplementation or assisted ventilation, duration of oxygen support, duration of ICU/ hospital stay and time for defervescence following initiation of oseltamivir therapy. Results: The mean age of the study population was 6.98 years. Majority of the affected children were > 5 years of age in the school going category with a male to female ratio of 3:2. The diagnosis based on clinical and radiological findings included upper respiratory tract infection (URTI) in 44 (78.5%) cases followed by pneumonia in 11(19.6%) and severe pneumonia in one (1.7%) child. The peak incidence was in the month of March. Malnutrition was the most common risk factor affecting 22 (39.3%) cases followed by history of asthma in eight (14.3%). Three children required oxygen supplementation at admission. The median duration of hospital stay was seven days. The median duration for defervescence following initiation of oseltamivir therapy was 24 hours. Mortality was recorded in one infant who died of acute respiratory distress syndrome. Conclusions: Influenza B virus should be screened in all children having underlying high risk medical condition, presenting with pneumonia or upper respiratory tract infection. Oseltamivir therapy should be initiated early in the management of influenza B viral infections to prevent complications.

scholarly journals A RANDOMISED CONTROL STUDY TO COMPARE THE EFFICACY OF CEFUROXIME, CLARITHROMYCIN, AND LEVOFLOXACIN IN THE MANAGEMENT OF PAEDIATRIC UPPER RESPIRATORY TRACT INFECTION

2021 ◽  
pp. 103-106
Author(s):  
GOUTHAMI PADUGUNDLA ◽  
JYOTHIRMAYEE V ◽  
BETHALA RAVALI ◽  
JAGILLAPURAM ARUNDHATHI ◽  
THAKUR SRILATHA ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Age Distribution ◽  
Age Groups ◽  
Efficacy Rate ◽  
Pool Data ◽  
Upper Respiratory Tract ◽  
Cure Rate ◽  
Significant Difference ◽  
Upper Respiratory ◽  
Tract Infections

Background: The upper respiratory infections cause considerable morbidity mainly in children due to the fact that they mainly affect children. Accordingly, a study was conducted on antibiotics to compare the effectiveness of clarithromycin, cefuroxime, and levofloxacin for treating upper respiratory tract infections (URTI) in children. Methods: A prospective observational study for a period of 6 months was conducted in the pediatrics department of RVM hospital. Outpatients under the age of 14 years given antibiotics for the treatment of URTI were included in the study. A total of 99 study subjects were included in the study, divided into three groups each containing 33 sample sizes (clarithromycin, cefuroxime, and levofloxacin). Patient data was collected using a form and verbal consent was obtained from patients/patient representatives, and drugs were given using the lottery method. Follow-up was done and noted for the 3rd, 5th, 7th day through telephonic calls, and the collected data were evaluated using statistical analysis. Results: Pool data from 99 patients shows that many patients belong to 0–5 years age groups (age distribution), and males were more than female (gender distribution). Clarithromycin (cure rate 3 days) and cefuroxime (cure rate 5 days) showed an equal rate of cure percentage (94%), while levofloxacin for 3–5 days with a 3% failure rate. A significant difference of p<0.05 (p=0.000) was observed and no adverse events were noted. Conclusion: The study findings showed, out of 3 drugs, clarithromycin and cefuroxime showed an equal efficacy rate of 94%, but clarithromycin showed shorter duration of outcome, i.e., 3 days. Hence, clarithromycin is effective than the other two drugs in the treatment of URTI.

Sign in / Sign up

Export Citation Format

Share Document